FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan
      Dashboard

      Eli Lilly to Initiate Phase 3 Trials for Combination Obesity Treatment

      Eli Lilly and Company announced plans to commence Phase 3 clinical trials for a combination obesity treatment regimen that includes its amylin drug, eloralintide, alongside tirzepatide. This decision follows promising results from mid-stage trials, which indicated that the combination therapy significantly enhances weight loss outcomes for participants.

      The Phase 3 trials are expected to begin by the end of 2026, marking a crucial step in the development of this innovative treatment. Eli Lilly aims to further evaluate the efficacy and safety of the combined regimen in a larger patient population, potentially paving the way for new options in obesity management.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud